0001636282SPYRE THERAPEUTICS, INC.S-8S-8EX-FILING FEESN/Axbrli:sharesiso4217:USDxbrli:pure000163628212025-08-052025-08-0500016362822025-08-052025-08-05
Exhibit 107
Calculation of Filing Fee Tables
FORM S-8 
(Form Type)
Spyre Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
 
        
Security
Type
 
Security
Class
Title (1)
 
Fee
Calculation
Rule
 
Amount
Registered
 
Proposed
Maximum
Offering
Price Per
Unit
 
Maximum
Aggregate
Offering Price
 Fee Rate 
Amount of
Registration
Fee
        
EquityCommon stock, par value $0.0001 per shareRule 457(a) (2)
750,000 (3)
$16.63$12,472,500.00
0.0001531
$1,909.54
Total Offering Amounts$12,472,500.00$1,909.54
Total Fee Offsets
Net Fee Due$1,909.54
 
 (1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”), that may be issued pursuant to the Registrant’s 2018 Equity Inducement Plan (as amended, the “2018 Plan”), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration that increases the number of the outstanding shares of the Registrant’s Common Stock.
 
 (2)Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on August 1, 2025.
 
 (3)Represents 750,000 additional shares of Common Stock to be registered and available for grant under the 2018 Plan.